Clinical Scorecard: Body Composition Analysis in Patients with Recently Diagnosed Multiple Myeloma
At a Glance
Category
Detail
Condition
Multiple Myeloma (MM)
Key Mechanisms
Assessment of skeletal muscle and adipose tissue content and quality via 18F-FDG PET/CT at L3 vertebral level to evaluate prognostic impact
Target Population
Newly diagnosed adult patients with multiple myeloma
Care Setting
Oncology and hematology clinical settings with access to PET/CT imaging
Key Highlights
Sarcopenia and adipose tissue distribution assessed by CT imaging have variable prognostic impacts in hematologic malignancies including MM.
18F-FDG PET/CT at diagnosis allows quantitative and qualitative body composition analysis in MM patients.
Body composition parameters such as skeletal muscle index (SMI) and adipose tissue indices are calculated using standardized CT attenuation thresholds and normalized for height.
Guideline-Based Recommendations
Diagnosis
Use 18F-FDG PET/CT imaging within 3 months prior to or within 1 month of treatment initiation for body composition analysis in MM.
Perform single-slice cross-sectional CT image analysis at L3 vertebral level for muscle and fat compartment segmentation.
Classify sarcopenia using sex-specific SMI cutoffs from literature or population medians.
Management
Incorporate body composition parameters alongside established prognostic factors to inform risk stratification.
Consider muscle and fat composition in treatment planning and supportive care to potentially improve outcomes.
Monitoring & Follow-up
Monitor progression-free survival (PFS) and overall survival (OS) in relation to baseline body composition parameters.
Use standardized statistical methods (Kaplan–Meier, Cox models) for outcome analysis.
Risks
Recognize variability in sarcopenia definitions and thresholds may affect prognostic interpretations.
Account for heterogeneity in patient populations and treatment regimens when evaluating body composition impact.
Patient & Prescribing Data
341 patients with newly diagnosed MM, median age 65, 66% male, majority receiving novel agent induction therapy
54% underwent transplantation; body composition analysis performed prior to or shortly after treatment initiation to assess prognostic significance
Clinical Best Practices
Use semi-automated software with manual correction for accurate segmentation of muscle and adipose tissue on CT images.
Apply sex-specific and BMI-adjusted cutoffs for defining sarcopenia to improve prognostic relevance.
Integrate body composition analysis into comprehensive patient assessment to guide personalized management.
by Nadine H. Abdallah, Hiroki Nagayama, Naoki Takahashi, Wilson Gonsalves, Amie Fonder, Angela Dispenzieri, David Dingli, Francis K. Buadi, Martha Q. Lacy, Miriam Hobbs, Morie A. Gertz, Moritz Binder, Prashant Kapoor, Rahma Warsame, Suzanne R. Hayman, Taxiarchis Kourelis, Yi L. Hwa, Yi Lin, Robert A. Kyle, S. Vincent Rajkumar, Stephen M. Broski, Shaji K. Kumar
